| Literature DB >> 31497886 |
Hou Bo1,2, David Heinzmann1, Christian Grasshoff3, Peter Rosenberger3, Christian Schlensak4, Meinrad Gawaz1, Jürgen Schreieck1, Harald F Langer5,6, Johannes Patzelt5,6, Peter Seizer1.
Abstract
BACKGROUND: Mitral regurgitation (MR) has a severe impact on hemodynamics and induces severe structural changes in the left atrium. Atrial remodeling is known to alter excitability and conduction in the atrium facilitating atrial fibrillation and atrial flutter. PMVR is a feasible and highly effective procedure to reduce MR in high-risk patients, which are likely to suffer from atrial rhythm disturbances. So far, electroanatomical changes after PMVR have not been studied. HYPOTHESIS: In the current study, we investigated changes in surface electrocardiograms (ECGs) of patients undergoing PMVR for reduction of MR.Entities:
Keywords: atrial conduction; atrial strain; electrocardiogram; mitral regurgitation; percutaneous mitral valve repair; remodeling
Mesh:
Year: 2019 PMID: 31497886 PMCID: PMC6837028 DOI: 10.1002/clc.23258
Source DB: PubMed Journal: Clin Cardiol ISSN: 0160-9289 Impact factor: 2.882
Figure 1Flow chart of patient cohort and evaluation strategy. Of 233 patients undergoing percutaneous mitral valve repair (PMVR), 104 patients were included in the study with electrocardiogram (ECG) in sinus rhythm at baseline and within the first 2 days after PMVR and/or at the follow‐up visit to evaluate P wave characteristics (a). Patients with a previous medical history of atrial fibrillation (AF) were included in the analysis when ECGs at the specified timepoints showed sinus rhythm. (b) illustrates obtained ECG measurements including P wave amplitude (a), P wave duration (b), PR interval (c), QRS duration (d), and QT interval (e) within the time course of PMVR
Baseline characteristics
| Variable | Study cohort (n = 104) | All screened patients (n = 233) |
|---|---|---|
| Age | 72.8 ± 10.8 (104) | 75.8 ± 9.3 (233) |
| Female gender | 43.3% (45/104) | 49.8% (117/233) |
| LV function | ||
| ≤ 35% | 52.0% (54/104) | 50.2 (117/233) |
| 36‐50% | 24.0% (25/104) | 25.3 (59/233) |
| > 50% | 24.0% (25/104) | 24.5% (57/233) |
| NYHA class pre | 3.2 ± 0.6 (101) | 3.1 ± 0.6 (228) |
| NYHA class FU | 2.1 ± 0.6 (65) | 2.3 ± 1.2 (151) |
| EuroSCORE II | 8.6 ± 6.9 (104) | 9.7 ± 8.8 (232) |
| Chronic renal failure | 51.0% (53/104) | 51.5% (120/233) |
| Coronary artery disease | 81.7% (85/104) | 75.5% (176/233) |
| Hypertension | 69.2% (72/104) | 73.4% (171/233) |
| Pulmonary hypertension | 57.3% (59/103) | 61.9% (143/231) |
| Diabetes mellitus | 29.8% (31/104) | 29.2% (68/233) |
| Insulin dependent diabetes | 12.5% (13/104) | 10.7 (25/233) |
| Previous cardiac surgery | 28.8% (30/104) | 30.0% (70/233) |
| Chronic lung disease | 7.7% (8/104) | 6.0% (14/233) |
| Recent myocardial infarction | 14.4% (15/104) | 12.4% (29/233) |
| Extracardiac arteriopathy | 24.0% (25/104) | 22.7% (53/233) |
| Hyperlipoproteinemia | 47.1% (49/104) | 47.6% (111/233) |
| MR preintervention (grades) | 3.5 ± 0.6 (104) | 3.5 ± 0.5 (233) |
| MR postintervention (grades) | 1.3 ± 0.7 (103) | 1.3 ± 0.7 (232) |
| MR at follow‐up (grades) | 1.7 ± 0.6 (71) | 1.7 ± 0.6 (161) |
| MR genesis functional | 45.1% (46/102) | 46.9% (107/228) |
| 6 min walk test preintervention (m) | 158 ± 124 | 145 ± 114 (142) |
| 6 min walk test at follow‐up (m) | 260 ± 133 | 265 ± 135 (127) |
| Average number of rehospitalizations for heart failure within 6 mo post intervention | 0.21 ± 0.48 (66) | 0.25 ± 0.53 (153) |
| Atrial fibrillation | 35.6% (37/104) | 65.2% (152/233) |
| LA diameter | 38.7 ± 9.3 (87) | 41.3 ± 10.4 (200) |
| Heart rate preintervention | 71 ± 15 (69) | 70 ± 16 (156) |
| Heart rate postintervention | 70 ± 21 (60) | 71 ± 19 (145) |
| Betablockers | 89.1% (90/101) | 90.0% (207/230) |
| ACE/AT1‐inhibitors | 82.2% (83/101) | 81.1% (185/228) |
| Aldosterone antagonist | 51.5% (52/101) | 50.9% (116/228) |
| Diuretics | 91.1% (92/101) | 88.6% (203/229) |
| Digitalis | 2.0% (2/101) | 9.6% (22/228) |
| Calcium antagonist | 15.3% (15/98) | 18.3% (41/224) |
| Anticoagulation | 45.1% (46/102) | 68.3% (157/230) |
Variables are expressed as mean ± SD.
Abbreviations: bpm, beats per minute; FU, follow‐up; LV, left ventricular; MR, mitral regurgitation; NYHA: New York Heart Association; y, years.
Figure 2Reduction of mitral regurgitation (MR) using percutaneous mitral valve repair (PMVR). MR grades of patients undergoing PMVR are illustrated pre‐ and post‐PMVR, as well as at follow‐up. Grading was performed according to the guidelines of the European Association of Echocardiography
Figure 3Reduction of mitral regurgitation using percutaneous mitral valve repair induces changes in atrial conduction. Surface ECGs of 104 patients with severe mitral regurgitation (MR) undergoing percutaneous mitral valve repair (PMVR) were analyzed. P wave duration in ms (a), P wave amplitude in mV (b), and PR interval in ms (c) are illustrated as mean ± SEM. All three parameters showed a significant decrease after reduction of MR. Parameters did not show significant changes during follow‐up. *indicates P < .05 compared to baseline; n.s. indicates P > .05 compared to post‐PMVR
Figure 4Ventricular excitation in surface electrocardiogram (ECG) does not change after PMVR. A total of 104 patients undergoing percutaneous mitral valve repair (PMVR) were analyzed regarding changes in QRS duration in ms (a), QT interval in ms (b), and QRS axis in degree (c). Reduction of mitral regurgitation using PMVR showed no significant change in ventricular excitation, neither shortly after the procedure nor at follow‐up. All parameters are shown as mean ± SEM, n.s. indicates P > .05